The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling

Stem Cell Research and Therapy

Volumn 7, Issue 1, 2016, Pages

  Barruet, Emilie ^a   Morales, Blanca M ^a   Lwin, Wint ^a   White, Mark P ^b   Theodoris, Christina V ^b   Kim, Hannah ^a   Urrutia, Ashley ^a   Wong, Sarah Anne ^a   Srivastava, Deepak ^b   Hsiao, Edward C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

Author keywords

Activin A signaling; ACVR1; BMP; Fibrodysplasia ossificans progressiva; hiPS derived endothelial cells; Tissue fibrosis

Indexed keywords

ACTIVIN A; ALKALINE PHOSPHATASE; ARGININE; BONE MORPHOGENETIC PROTEIN 4; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; HISTIDINE; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; ACTIVIN; ACTIVIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN; LIGAND; SMAD PROTEIN;

ACVR1 GENE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE; GENE MUTATION; HETEROTOPIC OSSIFICATION; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MOLECULAR PATHOLOGY; NONHUMAN; OSSIFYING MYOSITIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BONE DEVELOPMENT; CELL LINE; CHONDROGENESIS; GENETICS; METABOLISM; MUTATION; OSTEOBLAST; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; BONE MORPHOGENETIC PROTEIN 4; CELL DIFFERENTIATION; CELL LINE; CHONDROGENESIS; COLLAGEN; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIGANDS; MUTATION; MYOSITIS OSSIFICANS; OSSIFICATION, HETEROTOPIC; OSTEOBLASTS; OSTEOGENESIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84982104721     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-016-0372-6     Document Type: Article

References (48)

1. Hendricks HT, Geurts AC, van Ginneken BC, et al. Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury. Clin Rehabil. 2007;21:545-53.
2. Kocic M, Lazovic M, Mitkovic M, et al. Clinical significance of the heterotopic ossification after total hip arthroplasty. Orthopedics. 2010;33:16.
3. Leung C, Casey AT, Goffin J, et al. Clinical significance of heterotopic ossification in cervical disc replacement: a prospective multicenter clinical trial. Neurosurgery. 2005;57:759-63. discussion 759-63.
4. Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64:76-83.
5. Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22:191-205.
6. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525-7.
7. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.
8. Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30:379-90.
9. Medici D, Shore EM, Lounev VY, et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16:1400-6.
10. Le Bras A, Vijayaraj P, Oettgen P. Molecular mechanisms of endothelial differentiation. Vasc Med. 2010;15:321-31.
11. Hatsell SJ, Idone V, Wolken DM, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7:303ra137.
12. Hino K, Ikeya M, Horigome K, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112:15438-43.
13. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72.
14. Matsumoto Y, Hayashi Y, Schlieve CR, et al. Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013;8:190.
15. Spencer CI, Baba S, Nakamura K, et al. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Reports. 2014;3:269-81.
16. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell. 1990;62:1073-85.
17. White MP, Rufaihah AJ, Liu L, et al. Limited gene expression variation in human embryonic stem cell and induced pluripotent stem cell-derived endothelial cells. Stem Cells. 2013;31:92-103.
18. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-5.
19. Sidney LE, Branch MJ, Dunphy SE, et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32:1380-9.
20. Cai J, Orlova VV, Cai X, et al. Induced pluripotent stem cells to model human fibrodysplasia ossificans progressiva. Stem Cell Reports. 2015;5:963-70.
21. Collett GD, Canfield AE. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res. 2005;96:930-8.
22. Culbert AL, Chakkalakal SA, Theosmy EG, et al. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification. Stem Cells. 2014;32:1289-300.
23. de la Pena LS, Billings PC, Fiori JL, et al. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res. 2005;20:1168-76.
24. Maddaluno L, Rudini N, Cuttano R, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature. 2013;498:492-6.
25. Holtzhausen A, Golzio C, How T, et al. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J. 2014;28:1248-67.
26. Zhang H, Tian S, Klausen C, et al. Differential activation of noncanonical SMAD2/SMAD3 signaling by bone morphogenetic proteins causes disproportionate induction of hyaluronan production in immortalized human granulosa cells. Mol Cell Endocrinol. 2016;428:17-27.
27. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-84.
28. Cooley BC, Nevado J, Mellad J, et al. TGF-beta signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med. 2014;6:227ra234.
29. Correia AC, Moonen JR, Brinker MG, et al. FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-beta signaling. J Cell Sci. 2016;129:569-79.
30. Attisano L, Carcamo J, Ventura F, et al. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 1993;75:671-80.
31. Thomas PS, Sridurongrit S, Ruiz-Lozano P, et al. Deficient signaling via Alk2 (Acvr1) leads to bicuspid aortic valve development. PLoS One. 2012;7, e35539.
32. Yao Y, Shao ES, Jumabay M, et al. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol. 2008;28:2266-74.
33. Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14:1363-9.
34. Crisan M, Deasy B, Gavina M, et al. Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes. Methods Cell Biol. 2008;86:295-309.
35. Lounev VY, Ramachandran R, Wosczyna MN, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am. 2009;91:652-63.
36. Wosczyna MN, Biswas AA, Cogswell CA, et al. Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J Bone Miner Res. 2012;27:1004-17.
37. Suda RK, Billings PC, Egan KP, et al. Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells. 2009;27:2209-19.
38. Matsumoto Y, Ikeya M, Hino K, et al. New protocol to optimize iPS cells for genome analysis of fibrodysplasia ossificans progressiva. Stem Cells. 2015;33:1730-42.
39. Pessina P, Kharraz Y, Jardi M, et al. Fibrogenic cell plasticity blunts tissue regeneration and aggravates muscular dystrophy. Stem Cell Reports. 2015;4:1046-60.
40. McKleroy W, Lee TH, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304:L709-21.
41. Trappmann B, Gautrot JE, Connelly JT, et al. Extracellular-matrix tethering regulates stem-cell fate. Nat Mater. 2012;11:642-9.
42. Watt FM, Huck WT. Role of the extracellular matrix in regulating stem cell fate. Nat Rev Mol Cell Biol. 2013;14:467-73.
43. Kaneda H, Arao T, Matsumoto K, et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br J Cancer. 2011;105:1210-7.
44. Eijken M, Swagemakers S, Koedam M, et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J. 2007;21:2949-60.
45. Lowery JW, Intini G, Gamer L, et al. Loss of BMPR2 leads to high bone mass due to increased osteoblast activity. J Cell Sci. 2015;128:1308-15.
46. Sebald W, Nickel J, Zhang JL, et al. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem. 2004;385:697-710.
47. Aykul S, Martinez-Hackert E. Transforming growth factor-beta family ligands can function as antagonists by competing for type ii receptor binding. J Biol Chem. 2016;291:10792-804.
48. Sullivan MP, Torres SJ, Mehta S, et al. Heterotopic ossification after central nervous system trauma: a current review. Bone Joint Res. 2013;2:51-7.